ES2191260T3 - Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. - Google Patents
Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.Info
- Publication number
- ES2191260T3 ES2191260T3 ES98310580T ES98310580T ES2191260T3 ES 2191260 T3 ES2191260 T3 ES 2191260T3 ES 98310580 T ES98310580 T ES 98310580T ES 98310580 T ES98310580 T ES 98310580T ES 2191260 T3 ES2191260 T3 ES 2191260T3
- Authority
- ES
- Spain
- Prior art keywords
- imidazolidin
- ona
- derivatives
- useful
- target agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS REPRESENTADOS POR LA FORMULA 1: Y A SALES FARMACEUTICAMENTE ACEPTABLES Y A SOLVATOS DE LOS MISMOS, DONDE Z, R, R 3 Y R 4 REPRESENTAN LO QUE SE DEFINE EN LA DESCRIPCION. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS DE FORMULA 1 Y A PROCEDIMIENTOS DE INHIBICION DEL CRECIMIENTO CELULAR ANORMAL, INCLUYENDO CANCERES, EN UN MAMIFERO, MEDIANTE LA ADMINISTRACION DE DICHOS COMPUESTOS A DICHO MAMIFERO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7001097P | 1997-12-30 | 1997-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2191260T3 true ES2191260T3 (es) | 2003-09-01 |
Family
ID=22092561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98310580T Expired - Lifetime ES2191260T3 (es) | 1997-12-30 | 1998-12-22 | Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6080769A (es) |
EP (1) | EP0928788B1 (es) |
JP (1) | JPH11236333A (es) |
AT (1) | ATE232520T1 (es) |
BR (1) | BR9805734A (es) |
CA (1) | CA2257016C (es) |
DE (1) | DE69811329T2 (es) |
DK (1) | DK0928788T3 (es) |
ES (1) | ES2191260T3 (es) |
PT (1) | PT928788E (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000025789A1 (en) * | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | A method of treating endometriosis |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
AU2478500A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO2000034437A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
MXPA05006676A (es) * | 2002-12-19 | 2005-08-16 | Pfizer | Compuestos de indazol y composiciones farmaceuticas para inhibir proteinquinasas, y procedimientos para su uso. |
EP1740184A1 (en) * | 2004-03-30 | 2007-01-10 | Pfizer Products Incorporated | Combinations of signal transduction inhibitors |
WO2006021884A2 (en) | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
BRPI0514687A (pt) * | 2004-08-26 | 2008-06-17 | Pfizer | compostos amino heteroarila como inibidores de proteìna tirosina cinase |
ES2355923T3 (es) * | 2004-08-26 | 2011-04-01 | Pfizer, Inc. | Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa. |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
UA94060C2 (ru) * | 2005-09-07 | 2011-04-11 | Эмджен Фримонт Инк. | Моноклональное антитело, которое специфически связывает alk-1 |
JP5055284B2 (ja) | 2005-09-20 | 2012-10-24 | オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー | インシュリン様成長因子−1受容体キナーゼ阻害剤に対する抗癌応答を予測する生物学的マーカー |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
EP2400990A2 (en) | 2009-02-26 | 2012-01-04 | OSI Pharmaceuticals, LLC | In situ methods for monitoring the emt status of tumor cells in vivo |
EP2401614A1 (en) | 2009-02-27 | 2012-01-04 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2011091550A1 (en) | 2010-01-28 | 2011-08-04 | Bayer Materialscience Ag | High speed dvds |
US20110275644A1 (en) | 2010-03-03 | 2011-11-10 | Buck Elizabeth A | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
KR20130006464A (ko) * | 2010-03-09 | 2013-01-16 | 노버스 인터내쇼날 인코포레이티드 | 락톤 중간체를 통한 호모세린으로부터 메티오닌 또는 셀레노메티오닌의 제조 |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
EP3233829B1 (en) | 2014-12-18 | 2019-08-14 | Pfizer Inc | Pyrimidine and triazine derivatives and their use as axl inhibitors |
KR20180100125A (ko) | 2015-12-03 | 2018-09-07 | 아지오스 파마슈티컬스 아이엔씨. | Mtap 널 암을 치료하기 위한 mat2a 억제제 |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2100523T3 (es) * | 1992-01-16 | 1997-06-16 | Du Pont Merck Pharma | Nuevos liberadores de neurotransmisores utiles para la potenciacion de las facultades cognoscitivas. |
EP0746554A1 (en) * | 1994-02-23 | 1996-12-11 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
ES2203642T3 (es) * | 1995-06-07 | 2004-04-16 | Pfizer Inc. | Derivados de pirimidina heterociclicos con anillos condensados. |
IT1276781B1 (it) * | 1995-06-23 | 1997-11-03 | Gentili Ist Spa | Derivati antrachinonmono- e disolfon- sostituiti e composizioni farmaceutiche che li contengono per il trattamento delle patologie |
JPH09183725A (ja) * | 1995-09-01 | 1997-07-15 | Pfizer Inc | ガン治療用治療剤 |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
CA2259222A1 (en) * | 1996-06-27 | 1997-12-31 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
-
1998
- 1998-12-09 JP JP10350000A patent/JPH11236333A/ja active Pending
- 1998-12-22 DE DE69811329T patent/DE69811329T2/de not_active Expired - Fee Related
- 1998-12-22 DK DK98310580T patent/DK0928788T3/da active
- 1998-12-22 PT PT98310580T patent/PT928788E/pt unknown
- 1998-12-22 ES ES98310580T patent/ES2191260T3/es not_active Expired - Lifetime
- 1998-12-22 EP EP98310580A patent/EP0928788B1/en not_active Expired - Lifetime
- 1998-12-22 AT AT98310580T patent/ATE232520T1/de not_active IP Right Cessation
- 1998-12-24 CA CA002257016A patent/CA2257016C/en not_active Expired - Fee Related
- 1998-12-28 US US09/221,946 patent/US6080769A/en not_active Expired - Fee Related
- 1998-12-29 BR BR9805734-0A patent/BR9805734A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2257016C (en) | 2002-06-04 |
EP0928788B1 (en) | 2003-02-12 |
DE69811329T2 (de) | 2003-08-14 |
PT928788E (pt) | 2003-04-30 |
DK0928788T3 (da) | 2003-03-24 |
EP0928788A1 (en) | 1999-07-14 |
US6080769A (en) | 2000-06-27 |
ATE232520T1 (de) | 2003-02-15 |
BR9805734A (pt) | 2000-05-16 |
JPH11236333A (ja) | 1999-08-31 |
DE69811329D1 (de) | 2003-03-20 |
CA2257016A1 (en) | 1999-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2191260T3 (es) | Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. | |
PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
TR200201297T2 (tr) | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri. | |
EA200100135A1 (ru) | Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов | |
DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
AP9701039A0 (en) | Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one. | |
TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
ATE260255T1 (de) | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
SE9904508D0 (sv) | New compounds | |
EA200100983A1 (ru) | Производные 13-метилэритромицина | |
ES2168581T3 (es) | Derivados de indazol sustituidos. | |
PT992509E (pt) | Novos derivados macrolidos | |
PT916651E (pt) | DERIVADOS DE áCIDO FENILALQUILCARBOXILICO | |
EA200001157A2 (ru) | Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции | |
PT952157E (pt) | Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina | |
TR200102315T2 (tr) | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri. | |
BR9915898A (pt) | Compostos, composição farmacêutica, e, utilização de um composto |